Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
about
Antiseptics and disinfectants: activity, action, and resistanceThe use of the dried blood spot sample in epidemiological studiesHuman immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individualsUses of inorganic hypochlorite (bleach) in health-care facilitiesAdvantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing ProcessBiosafety considerations for flow cytometric analysis of human immunodeficiency virus-infected samples.Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.The effect of blood on the antiviral activity of sodium hypochlorite, a phenolic, and a quaternary ammonium compound.Impact of collection method on assessment of semen HIV RNA viral loadLipid composition and fluidity of the human immunodeficiency virus.The health worker and HIV in high-incidence poor countries: part 2--HIV disinfection.Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyondHIV disease and the gastroenterologistThe sclera, the prion, and the ophthalmologist.Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force.Surgical outcomes of different Ahmed Glaucoma Valve implantation methods between scleral graft and scleral flap.Effects of supraphysiologic temperature and broth dilution on serum protein binding.Presence of human immunodeficiency virus nucleic acids in wastewater and their detection by polymerase chain reactionModel for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility.Filter paper sampling of blood infected with HIV: effect of heat on antibody activity and viral infectivity.Recovery of the human immunodeficiency virus from fibreoptic bronchoscopes.Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.Efficiency of human immunodeficiency virus transmission through injections and other medical procedures: evidence, estimates, and unfinished business.Practical diagnostic testing for human immunodeficiency virus.Transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health care settings: a review of risk factors and guidelines for prevention. World Health OrganizationEnergy dispersive analysis of X-rays study of the distribution of chlorhexidine diacetate and cetylpyridinium chloride on the Pseudomonas aeruginosa bacteriophage F116.Enzyme immunoassay with enhanced specificity for detection of antibodies to Chlamydia trachomatisCell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.Recovery of human immunodeficiency virus type 1 from supernatant fluid of routine viral cultures.Isolation of Ureaplasma urealyticum and Mycoplasma hominis from public toilet bowls.AIDS and the lung. 1--AIDS, aprons, and elbow grease: preventing the nosocomial spread of human immunodeficiency virus and associated organisms.AIDS update: prevalence, prevention, and medical management.Paper microfluidics for nucleic acid amplification testing (NAAT) of infectious diseases.A comparison of male and female intravenous drug users' risk behaviors for HIV infection.Stability of infectious HIV in clinical samples and isolation from small volumes of whole blood.Infection control revisited: dilemma facing today's bronchoscopists.Survival of human immunodeficiency virus in suspension and dried onto surfaces.Immunofluorescence assay for human immunodeficiency virus antibody: investigation of cell fixation for virus inactivation and antigen preservation.Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus.The role of bronchoscopy in patients with HIV disease.
P2860
Q24550729-9C700DFC-F388-4DF4-B0C7-A5D758702C96Q24563605-DB5DFA3A-EC29-4ECE-B94D-7E50290EE250Q24647035-BF74123F-2490-4B33-9746-3518256E467BQ28379190-E5BD843E-0A45-472E-8639-7104FA4DE8E5Q29109543-62D826F8-AAC2-45E0-9517-C84CCB52E680Q33749451-6DB68EF6-2608-4415-BD7D-162E990AE51DQ33806303-7F9C2E97-0BF9-4416-9DFA-DC97548B8379Q33885032-16F29398-4493-4ED6-ACD5-527F828BCE05Q34008885-7D80326E-C69C-43F1-A963-1D2C3EBAB698Q34048036-FE3C3675-0F1B-495D-B50D-4733818EDC62Q34081220-F9EBE78A-7C01-41E8-8126-BDD29F7EB37AQ34196397-7F243EB2-0266-4600-9EA4-42D0117DA8A4Q34530800-D89BB1AA-3D54-4F35-A561-FE19A6E47E68Q34612626-1E6BE6C7-D965-481B-92EB-EE0534158D8BQ35039821-8FA9D637-33EF-4398-9C04-F126F4F641E3Q35228422-2F285F3F-B74B-4AD8-B3A9-961F6B67D2D0Q35263450-52314509-9B4B-4FFB-A102-861367DE3E18Q35699303-2BA55D89-355C-4B7C-BDB1-D14E67D0795AQ35700370-2A194793-B68D-4008-8A9B-7A87FE664E6DQ35705379-1216007E-443E-4E5C-964D-FBABF4D86B69Q36245349-49E02AFF-B475-42CD-9CC3-AD8B7F8DE878Q36342211-7306F1F0-7CBC-4336-A332-2D1A21C6AFACQ36581538-F70BF756-6FFF-4AC1-A7F2-60E2A19B1563Q36632724-EBDBC8BC-9D39-4975-AE75-BEFF29C1667FQ36669093-9C2BA0AC-474B-44C2-A648-A0B751830A41Q36708271-C9C61789-0CA7-45D3-83DA-DC9888B9F93DQ37092325-C64B89FC-5EAB-4FC7-A4F0-1C9E70C2BB00Q37131155-7D474456-509E-48FA-BFA9-C9EDBDB977D1Q37177362-4BB767FA-F568-4E17-92F2-94D3DE82F106Q37879222-A94E69D0-60D7-487F-8FE2-5FF1BA1F5387Q38735596-203F0DDE-0576-427D-833B-AB4F6F2315F3Q38765913-B862209E-E5A0-4CAB-A822-747AC2A62508Q39385787-C449E0FA-4771-4CCD-AFEC-EE85050C698BQ39395283-B1FF5F0F-0C88-4851-BE4A-DC87EF553B35Q39628363-476032AC-6AC8-4D81-9C42-A0530BDDA8C6Q39715009-8B62BBAA-724D-49E0-9DEE-7FAA52C0EAC4Q40175852-EFAF8DDB-075D-48D1-BC3E-485D7C2F0622Q40200402-EE1BDE68-6601-4E38-A30E-A93883B025D1Q40208864-A46780A6-B4CF-40BE-8C3E-011F1093DE56Q40689241-2E18ACE3-1AF3-4745-BA49-C0ADD3BC0352
P2860
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
description
1986 nî lūn-bûn
@nan
1986 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@ast
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@en
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@nl
type
label
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@ast
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@en
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@nl
prefLabel
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@ast
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@en
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@nl
P2093
P1476
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.
@en
P2093
P D Markham
S Tondreau
S Z Salahuddin
P304
P356
10.1001/JAMA.1986.03370140085029
P407
P577
1986-04-01T00:00:00Z